New Study Confirms Physician-Led Biologic Dose Reduction Is Safe and Effective for Psoriasis (BeNeBio)
Managing psoriasis doesn't require lifetime, full-dose systemic therapy. The BeNeBio study published in The Lancet¹, confirms that IL-17 and IL-23 inhibitor doses can often be safely reduced under physician guidance– avoiding unnecessary drug exposure without compromising disease control.
Key Highlights
First Across All Agents
BeNeBio tested dose reduction across all seven registered IL-17 and IL-23 inhibitors— the first trial to do so. What that means for how health plans manage psoriasis and eczema spend is in the brief.
73.2% Maintained; Here’s Why
73.2% of patients who reduced dose under physician guidance held disease control at 18 months. What's behind that number, and why most practices can't replicate it, is where this gets interesting.
Evidence Isn't Execution
BeNeBio shows remission can be held on less drug. It doesn't answer who can act on that at scale, or why most health plans still can't. That's the open question and this brief answers it.
Let's work together
Partner with Zest Health to implement smarter, more cost-effective psoriasis and eczema care for your workforce, members, or clients. We're here to help you make a difference.
Get in touch